Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of Chinese ancestry~* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to study start~* Have plaque-type psoriasis covering at least 10% of total BSA at screening and at the time of study start~* Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start~* Must be candidates for phototherapy or systemic treatment of psoriasis (either naive or history of previous treatment)~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis~* Have current drug-induced psoriasis~* Have used any investigational drug within the previous 4 weeks~* Have used any biologic within the previous 3 months~* Be known to be infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
- 002 (Type: EXPERIMENTAL): placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16

Based on this trial design, predict the completion outcome and termination type (if applicable).